Lexicon Q2 FY26 net loss widens to $31.8 million; revenue drops to $0.7 million

LXRX•2026-08-06

Cash position and pipeline updates

Cash and investments totaled $190.6 million at June 30, 2026; it also put in place a $100 million Hercules Capital loan facility.

Enrollment finished in the Phase 3 SONATA-HCM trial with top-line data expected in Q1 2027; ZYNQUISTA NDA resubmission targeted for Q4 2026.

Q2 results show wider loss and lower revenue

Lexicon posted Q2 2026 revenue of $0.7 million, down 97.58% from a year earlier.

Net loss widened to $31.8 million, or $0.07 per share, swinging from net income of $3.3 million, or $0.01 per share.

R&D expenses rose to $17.4 million; SG&A expenses increased to $9.8 million.

Sources

Lexicon Q2 FY26 net loss widens to $31.8 million; revenue drops to $0.7 million

Sec

Lexicon Q2 FY26 net loss widens to $31.8 million; revenue drops to $0.7 million

Cash position and pipeline updates

Q2 results show wider loss and lower revenue

Related News

Revolution Medicines, Inc. <RVMD.O>: Wedbush raises target price to $201 from $192.1

Helix Energy Q2 revenue misses estimates, withdraws annual guidance

Aurinia Q2 net income climbs 74% to $37.4 million; revenue rises 19% to $83.2 million

Sources

Lexicon Q2 FY26 net loss widens to $31.8 million; revenue drops to $0.7 million

Rezolve Ai publishes update to financial calendar

Nano-X Imaging prices USD 8 million registered direct offering at USD 1 per share with warrants